Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER): Study design and progress update (P5.126)

Conclusion:The GRIPPER study may provide clinically relevant outcomes data for CIDP patients receiving IVIg and explore the relationship between IVIg dosing, interval, and treatment-related fluctuations in routine clinical practice. Patient recorded GS is feasible and practical. Serum IgG levels and clinical response to IVIg may develop better evidence based dosing strategies.Study Supported by:Supported by CSL Behring - investigator-initiated study grant.Disclosure: Dr. Allen has nothing to disclose. Dr. Pasnoor has nothing to disclose. Dr. Burns has received personal compensation in an editorial capacity for the Neurology podcast. Dr. Ajroud-Driss has nothing to disclose. Dr. Cook has nothing to disclose. Dr. Brannagan has received personal compensation from Grifols, Catalyst, and Baxter. Dr. Lawson has nothing to disclose. Dr. Ney has received personal compensation for activities with Surgical Neuromonitoring, PLLC, and Surgical Neuromonitoring Associates. Dr. Kissel has received personal compensation for activities with AveXis, Inc. Dr. Gorson has received personal compensation for activities with Grifols, UCB Pharma, AxelaCare, Annexon, and Prophase. Dr. Lewis has received personal compensation from CSL Behring, Pharnext and Novartis and Axelacare. Dr. Walton has received personal compensation for activities with AxelaCare Health Solutions.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Allen, J., Pasnoor, M., Burns, T., Ajroud-Driss, S., Cook, A., Brannagan, T., Lawson, V., Ney, J., Kissel, J., Gorson, K., Lewis, R., Walton, T. Tags: Neuromuscular and Clinial Neurophysiology (EMG): Peripheral Neuropathy II Source Type: research